Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 and Camrelizumab in Recurrent Cervical Cancer
NCT05234905Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of Oncorine in Cervical Cancer (CC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
Oncorine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05234905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234905.